A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2019
Price : $35 *
At a glance
- Drugs Efatutazone (Primary)
- Indications Myxoid liposarcoma
- Focus Therapeutic Use
- 31 Aug 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
- 31 Aug 2018 Biomarkers information updated
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.